Nephosity, a digital health startup that was a member of Rock Health’s second class, has received clearance from the United States Food and Drug Administration (FDA) for their MobileCT Viewer, a software application for diagnostic image viewing on the iPad.
In this video, a representative at Nephosity demonstrates MobileCT, an app for mobile collaborative teleradiology. It allows for a user (such as a doctor or patient) to use their mobile devices to view x-rays, MRIs, etc., and to collaborate with other users (such as other doctors or relatives).
Professor Brian T. Cunningham and his graduate students demonstrate their development of using a smartphone camera as a high resolution spectrophotometer. Cunningham’s group is now collaborating with other groups across campus at the U. of I. to explore applications for the iPhone biosensor.
Researchers and physicians in the field could soon run on-the-spot tests for environmental toxins, medical diagnostics, food safety and more with their smartphones. University of Illinois at Urbana-Champaign researchers have developed a cradle and app for the iPhone that uses the phone’s built-in camera and processing power as a biosensor to detect toxins, proteins, bacteria, viruses, and other molecules.
National Lung Screening Trial investigators also conclude that the 20 percent reduction in lung cancer mortality with low-dose computed tomography versus chest X-ray screening previously reported in the NLST primary paper is achievable at experienced screening centers in the United States.
First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer DetectionMay 23, 2013 10:28 am | by PR Newswire | News | Comments
Hologic, Inc. has announced that the first large-scale observational study in a U.S. clinical practice comparing breast cancer screening with Hologic's 3D mammography technology with conventional 2D mammography alone showed a significant reduction in recall rates and a sizeable increase in cancer detection, particularly invasive cancer, across all breast tissue densities.
TOPS Comprehensive Breast Center Study Validates the Benefits of New 3D Mammography Technology in Breast Cancer ScreeningMay 23, 2013 10:24 am | by The Associated Press | News | Comments
HOUSTON--(BUSINESS WIRE)--May 23, 2013--The first large-scale U.S. study comparing conventional 2D mammography screening exams alone versus 2D mammography with the addition of 3D mammography (breast tomosynthesis) technology has been completed at TOPS Comprehensive Breast Center. The study showed...
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, will display its ForeCYTE Breast Health Test at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, from May 31 through June 4, 2013. Atossa's exhibit will be located in booth 2019...
TEL AVIV, Israel, May 23, 2013 /PRNewswire/ -- Israel Brain Technologies (IBT) has announced the launch of BrainTech Israel 2013, Israel's 1st International Brain Technology Conference, which will take place on October 14th-15th in Tel Aviv, recently ranked as the 2nd most innovative...
The Selenia Dimensions 3D System is comprised of hardware and software upgrades to the Selenia Dimensions 2D full-field digital mammography system, which is FDA approved for conventional mammography. The hardware upgrades produces multiple, low-dose x-ray images of the breast; the software upgrade uses the low-dose x-ray images to create cross-sectional (tomosynthesis) views of the breast.
Cognoptix Test Identifies Alzheimer’s Disease via Beta Amyloid Signature in the Eyes in Proof-of-Concept Clinical TrialMay 22, 2013 12:53 pm | by The Associated Press | News | Comments
ACTON, Mass.--(BUSINESS WIRE)--May 22, 2013--Cognoptix, an emerging medical device company, announced today that its SAPPHIRE II eye test identified Alzheimer’s disease patients via a beta amyloid (“Ab”) signature in their eyes in a 10-subject proof-of-concept clinical trial.
New Data on Cellvizio Presented at DDW 2013 Suggests That Optical Biopsies May Help Confirm and Rule Out Pancreatic Cystic Tumors*May 22, 2013 11:45 am | by The Associated Press | News | Comments
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, today announced that optical biopsies using a microscope so tiny it fits through a small needle show clear cellular-level images inside pancreatic cysts,...
DENVER--(BUSINESS WIRE)--May 22, 2013--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that it has entered into a collaboration agreement with Eli Lilly and Company (NYSE: LLY) to develop diagnostic technology in support of a...
Waterproof fabrics that whisk away sweat could be the latest application of microfluidic technology developed by bioengineers at the University of California, Davis. The new fabric works like human skin, forming excess sweat into droplets that drain away by themselves, said inventor Tingrui Pan, professor of biomedical engineering.
Graduate students developed a new textile microfluidic platform using hydrophilic threads stitched into a highly water-repellent fabric. The new fabric works like human skin, forming excess sweat into droplets that drain away by themselves, said inventor Tingrui Pan, professor of biomedical engineering.
Merge Healthcare Incorporated, a leading provider of clinical systems and innovations that seek to transform healthcare, today announced that St. Joseph's Imaging of Syracuse, NY has selected Merge's Outpatient Radiology Suite consisting of Merge's radiology information system, picture achieving communication solution, document management, referring physician engagement and medical image sharing solution.
Covidien’s Technology Platform to Diagnose Early Lung Cancer Part of New Guidelines of American College of Chest PhysiciansMay 21, 2013 6:59 am | by The Associated Press | News | Comments
MINNEAPOLIS--(BUSINESS WIRE)--May 21, 2013--Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that its superDimension Electromagnetic Navigation Bronchoscopy (ENB™) system, the first technology of its kind, is included in the new American College of Chest...
Given Imaging Announces Data Confirming PillCam(R) SB Improves Monitoring and Management of Crohn's DiseaseMay 21, 2013 4:45 am | by GlobeNewswire | News | Comments
Given Imaging, a world leader in specialty GI products and pioneer of capsule endoscopy, today announced new studies that confirm the value of PillCam SB in diagnosing, monitoring and managing patients with known or suspected Crohn's disease and other conditions of the small bowel.
VerrataT Pressure Guide Wire and iFR@ (Instant Wave-Free RatioT) Software Modality will be on display at EuroPCR 2013May 21, 2013 4:40 am | by The Associated Press | News | Comments
Volcano Corporation (NASDAQ: VOLC) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will demonstrate the VerrataT Pressure Guide Wire and the iFR@ (Instant...
Given Imaging Announces New European Study Evaluating PillCam(R) COLON versus CT-Colonography in Patients With Incomplete ColonoscopyMay 20, 2013 4:45 pm | by GlobeNewswire | News | Comments
Given Imaging Ltd, a world leader in GI medical devices and pioneer of capsule endoscopy, today announced data from several European studies confirming the effectiveness of PillCam COLON in detecting colonic lesions in patients following incomplete colonoscopies and monitoring diverse digestive diseases in both adults and children.
Emergency physicians are key decisionmakers for nearly half of all hospital admissions, highlighting a critical role they can play in reducing health care costs, according to a new report from the RAND Corporation. Hospital admissions from the ER increased by 17 percent over seven years, accounting for nearly all the growth in hospital admissions between 2003 and 2009.
The study comprised over 24,000 Finnish subjects and was led by Professor Samuli Ripatti. The results revealed that a panel of 28 genetic markers improved detection of individuals with high risk for coronary heart disease (CHD) (10-year risk ≥20%) over traditional risk factors.
EL SEGUNDO, Calif., May 20, 2013 /PRNewswire/ -- A medical diagnostic technology that experts at Wyle helped perfect for use both in space and on Earth was inducted recently in the Space Technology Hall of Fame. The technology assures high quality, secure handling and transmission of...
PENTAX Medical Continues Global Leadership in Endoscopic Ultrasound Systems with Release of the Hi Vision PreirusMay 20, 2013 11:08 am | by PENTAX Medical Company | News | Comments
PENTAX Medical Company, a healthcare industry leader in endoscopic imaging, recently announced the release of the HI VISION™ Preirus™ ultrasound scanner. PENTAX Medical, in collaboration with Hitachi-Aloka, has had a rich history of introducing ultrasound scanners to the gastroenterology and pulmonary markets that present new possibilities in imaging capabilities.
New Diagnostics Solutions from Welch Allyn to Help Improve Patient Safety, Reduce Risk for FacilitiesMay 20, 2013 11:05 am | by Welch Allyn | News | Comments
Welch Allyn, a leading medical diagnostic device company that specializes in helping clinicians improve patient outcomes, will showcase its new FlexiPort® EcoCuffTM blood pressure cuff and EarlySense Vitals Surveillance System at the National Teaching Institute & Critical Care Exposition this week at the Boston Convention & Exhibition Center in Boston, Mass.